An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Available (expanded access)

Conditions studied: Lennox Gastaut Syndrome

In brief

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Key facts

Study ID

NCT03778424

Run by

Eisai Inc.

Last updated by the study team

2026-07-08

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.

You may not qualify if…

• Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.

Where it is running

• Generała Tadeusza Kościuszki 52 — Kielce, Poland
• Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu — Poznan, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.